• ABOUT
  • PRIVACY
  • CONTACT
  • ADVERTISE
No Result
View All Result
KeralaNews 24x7
Sunday, June 8, 2025
  • HOME
  • NEWS
  • ENTERTAINMENT
  • CRYPTO
  • SPORTS
    • OLYMPIC
    • CRICKET
    • FOOTBALL
    • KABADDI
    • BASKETBALL
    • TENNIS
    • WWE
  • TECHNOLOGY
  • HEALTH
  • EVENTS
  • DEALS
    • SPECIAL DEALS
  • BLOG
    • BUSINESS
    • FINANCE
    • DIGITAL MARKETING
    • EDUCATION
    • LIFE STYLE
    • REAL ESTATE
    • ART
    • ADULT
    • CASINO
    • FASHION
    • GAMES
    • LAW AND ORDER
    • TRAVEL
  • HOME
  • NEWS
  • ENTERTAINMENT
  • CRYPTO
  • SPORTS
    • OLYMPIC
    • CRICKET
    • FOOTBALL
    • KABADDI
    • BASKETBALL
    • TENNIS
    • WWE
  • TECHNOLOGY
  • HEALTH
  • EVENTS
  • DEALS
    • SPECIAL DEALS
  • BLOG
    • BUSINESS
    • FINANCE
    • DIGITAL MARKETING
    • EDUCATION
    • LIFE STYLE
    • REAL ESTATE
    • ART
    • ADULT
    • CASINO
    • FASHION
    • GAMES
    • LAW AND ORDER
    • TRAVEL
No Result
View All Result
News 24x7
No Result
View All Result

Akums Drugs & Pharmaceuticals: Citi Sees 36% Upside—Should Investors Buy?

Satish Ray by Satish Ray
3 months ago
Reading Time: 2 mins read
0
0
0
SHARES
1
VIEWS
FBXLinkedinWhatsAppTelegram

Akums Drugs & Pharmaceuticals Ltd., a key player in India’s contract drug manufacturing space, has caught the attention of investors after global brokerage firm Citi reaffirmed its bullish stance. With a target price of Rs 700 per share, the stock could deliver a potential 36% upside from current levels. But does it justify a buy?

Stock Holding Steady Despite Market Volatility

Shares of Akums Drugs & Pharmaceuticals Ltd. were trading at Rs 516 per share on Thursday, reflecting a marginal dip of 0.2% from the previous day’s close. The company’s market capitalization stood at Rs 8,229.97 crore, solidifying its presence as a dominant contract development and manufacturing organization (CDMO) in the Indian pharma sector.

While broader market fluctuations have weighed on sentiment, Citi remains optimistic. The firm believes the company’s long-term growth potential outweighs short-term concerns, particularly given its latest contract wins and international expansion plans.

Akums Drugs Pharmaceuticals factory

What’s Driving the 36% Upside?

A major catalyst for Citi’s bullish call is Akums’ recent 200-million-euro CDMO contract with a global pharmaceutical player. The company has already secured half of the deal’s value, boosting confidence in its execution capabilities.

  • Akums is India’s largest domestic-focused CDMO and the second-largest overall.
  • The company benefits from large-scale operations, strong manufacturing capabilities, and an expanding international footprint.
  • API price corrections and weaker CDMO revenues in the past year created temporary headwinds, but Citi expects recovery in H1FY26E.

Further, Akums is aggressively expanding its production facilities in Hardwar and Baddi, setting the stage for a more prominent global presence. The company trades at 12x FY27E EBITDA, significantly below its closest competitor, which Citi values at 15x CDMO EBITDA and 10x non-CDMO EBITDA.

Financials: Short-Term Pain, Long-Term Gain?

Akums reported Q3 FY25 revenues of Rs 1,010 crore, down from Rs 1,083 crore in the same quarter last year. Net profit plunged to Rs 66 crore from Rs 195 crore in Q3 FY24, raising concerns about earnings stability.

However, the operating margin improved to 12% from 9%, indicating better cost management despite revenue declines. Key financial metrics include:

MetricQ3 FY25Q3 FY24
Revenue (Rs Cr)1,0101,083
Net Profit (Rs Cr)66195
Operating Margin12%9%
ROE9.8%N/A
ROCE7.5%N/A

Despite the dip in earnings, Citi believes that the upcoming recovery in CDMO revenues will drive a rebound in valuation.

Should Investors Buy?

Citi’s 36% upside target paints an optimistic picture. However, investors must weigh the short-term financial pressures against the company’s long-term growth strategy. The API pricing environment remains challenging, and near-term earnings volatility is a risk. Yet, Akums’ aggressive expansion, strong CDMO positioning, and valuation discount to peers make it a compelling stock to watch in the Indian pharma space.

One thing’s clear: the next few quarters will be crucial in determining whether Akums lives up to Citi’s expectations.

ShareTweetShareSendShare
Satish Ray

Satish Ray

Satish Ray is a senior content writer with a penchant for weaving words into captivating narratives. With years of experience in crafting compelling stories across diverse industries, he excels in delivering engaging content that resonates with readers and drives results.

Related Posts

punjab national bank building india

Punjab National Bank Slashes Lending Rates After RBI’s Bold Repo Cut

22 hours ago
snapdragon-8-elite-chipset-qualcomm-2025-devices

Snapdragon 8 Elite Defines 2025’s Mobile Revolution — One Form Factor at a Time

23 hours ago
resident evil requiem reveal summer game fest 2025

Capcom Unveils Resident Evil Requiem, A Bold New Chapter in the Franchise’s 30-Year Legacy

23 hours ago
Indian stock market Sensex Nifty June 2025 midday trading

Sensex and Nifty Surge Midday, Led by Finance and Auto Stocks on June 6, 2025

23 hours ago
Nintendo Switch 2 console gaming performance improvement

Nintendo’s Switch 2 Surprises Fans with Free Performance Boost for Original Games

2 days ago
Aaron Rodgers Pittsburgh Steelers 2025 signing announcement

Aaron Rodgers Joins Pittsburgh Steelers in a Move That Shakes Up the NFL Landscape

2 days ago
Western Carriers logistics truck inside industrial plant

Western Carriers Secures ₹27.73 Crore Contract from Jindal Stainless for Jaipur Plant Logistics

2 days ago
Ivanka Trump Miami vacation book Untamed Glennon Doyle Instagram

Ivanka Trump Shares Glennon Doyle’s ‘Untamed’ Amid Political Tensions

4 days ago

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

SEARCH

No Result
View All Result

ADVERTISEMENTS

(adsbygoogle = window.adsbygoogle || []).push({});

POPULAR ARTICLES

Waveform

How to Draw a Waveform: Step-by-Step Guide

1 year ago
Crypto Transaction

How Cryptocurrency Transaction Works? Read Pros & Cons of Cryptocurrency

3 years ago
eSports

Just How Big Will eSports Be?

8 years ago
Iontophoresis Device

Iontophoresis Device, the Best Treatment for Excessive Sweating

8 years ago
NOW Entertainment soon to Start Selling American Hustle82 Apparel

NOW Entertainment soon to Start Selling American Hustle82 Apparel

8 years ago
E-cigs Products in Classrooms

Is It Right to Ban the Juul and Other E-cigs Products in Classrooms?

8 years ago
Ryan Van Wagenen

Ryan Van Wagenen Expects Continued Growth for the Silicon Slopes

7 years ago
Working Remotely: Benefits for Employers and Employees

Working Remotely: Benefits for Employers and Employees

7 years ago
Benefits of installing Solar on your house

Benefits of installing Solar on your house

7 years ago
Casino Hacked using a Smart Thermometer

Casino Hacked using a Smart Thermometer

7 years ago
Facebook Twitter Youtube

ABOUT US

The KeralaNews 24×7 website is for desi entertainment lovers across India, USA and UK. We often cover breaking News & Trending topics in India and have been referenced by numerous media outlets. Follow us on our Social media profiles for the latest updates and news.

Contents produced in this website are subjected to DigitalCopyRight Law.

© 2023 KeralaNews 24×7 – Website Designed by VISION

WEBSITE STATS

  • Google News Approved
  • 1,00,000 Traffic/Month
  • Domain Authority – 25
  • 70% Traffic from Google

ADVERTISE WITH US

If you are looking to advertise your business or website, feel free to contact us at ceo.keralanews247@gmail.com

We accept following form of advertisements,

  • Banner Ads
  • Contextual Links
  • Guest Posts
  • Sponsored Posts

SEARCH

No Result
View All Result

MORE INFO

  • ABOUT
  • PRIVACY
  • CONTACT
  • ADVERTISE

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • HOME
  • NEWS
  • ENTERTAINMENT
  • CRYPTO
  • SPORTS
    • OLYMPIC
    • CRICKET
    • FOOTBALL
    • KABADDI
    • BASKETBALL
    • TENNIS
    • WWE
  • TECHNOLOGY
  • HEALTH
  • EVENTS
  • DEALS
    • SPECIAL DEALS
  • BLOG
    • BUSINESS
    • FINANCE
    • DIGITAL MARKETING
    • EDUCATION
    • LIFE STYLE
    • REAL ESTATE
    • ART
    • ADULT
    • CASINO
    • FASHION
    • GAMES
    • LAW AND ORDER
    • TRAVEL

© 2023 KeralaNews 24x7 - Website Designed by VISION

This website uses cookies. By continuing to use this website you are giving consent to cookies being used. Visit our Privacy and Cookie Policy.